Evidence map›Paper›PMID 34164811›Full record

ArticleEuropean journal of clinical investigation2021

IFN-γ

Alejandro Vallejo, Pilar Vizcarra, Carmen Quereda, Ana Moreno, José Luis Casado, CoVEX study group

Open access · bronzeAbstract read
In one paragraph

Article in European journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  6. IFN-γEuropean journal of clinical investigation · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alejandro VallejoLaboratory of Immunovirology, Department of Infectious Diseases, Ramon y Cajal Health Research Institute (IRyCIS), University Hospital Ramon y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0001-5360-878X
Pilar VizcarraDepartment of Infectious Diseases, Ramon y Cajal Health Research Institute (IRyCIS), University Hospital Ramon y Cajal, Madrid, Spain.
Carmen QueredaDepartment of Infectious Diseases, Ramon y Cajal Health Research Institute (IRyCIS), University Hospital Ramon y Cajal, Madrid, Spain.
Ana MorenoDepartment of Infectious Diseases, Ramon y Cajal Health Research Institute (IRyCIS), University Hospital Ramon y Cajal, Madrid, Spain.
José Luis CasadoDepartment of Infectious Diseases, Ramon y Cajal Health Research Institute (IRyCIS), University Hospital Ramon y Cajal, Madrid, Spain.
CoVEX study group
Instituto Cajal · ES

Funding

Instituto de Salud Carlos III covid20-1304
6 · The paper itself

Abstract

backgroundHealthcare workers (HCWs) are at increased risk since they are directly exposed to SARS-CoV-2-infected patients, and nevertheless, some remain without the development of anti-SARS-CoV-2 antibodies or related symptoms, suggesting less susceptibility to the infection.

methodsThis cross-sectional, case-control study aimed to compare SARS-CoV-2 T-cell response by two different technologies, the analysis of IFN-γ

resultsA high proportion of uninfected HCWs (53.8%) had pre-existing IFN-γ

conclusionsThe good concordance between the proportion of individuals with IFN-γ release after SARS-COV-2 stimulation with the proportion of individuals with specific IFN-γ

Indexed as

AdultCase-Control StudiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCoronavirus M ProteinsCoronavirus Nucleocapsid ProteinsCOVID-19Cross-Sectional StudiesFemaleHealth PersonnelHumansInterferon-gammaInterferon-gamma Release TestsIn Vitro TechniquesMaleMiddle AgedCoronavirus M ProteinsCoronavirus Nucleocapsid ProteinsInterferon-gammamembrane protein, SARS-CoV-2nucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Matrix Proteinscellular immune responseCOVID-19exposed healthcare workersSARS-CoV-2

Identifiers

PMID34164811
PMCPMC8420579
OpenAlexW3175578001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.